{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T09:30:13Z","timestamp":1760866213676,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s40268-019-00291-2","type":"journal-article","created":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T16:03:12Z","timestamp":1575907392000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Extrapolation of Drug Clearance in Children \u2264\u20092\u00a0Years of Age from Empirical Models Using Data from Children (&gt;\u20092\u00a0Years) and Adults"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1311-4237","authenticated-orcid":false,"given":"Iftekhar","family":"Mahmood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,9]]},"reference":[{"key":"291_CR1","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMra035092","volume":"349","author":"GL Kearns","year":"2003","unstructured":"Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157\u201367.","journal-title":"N Engl J Med"},{"key":"291_CR2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40262-014-0134-5","volume":"53","author":"I Mahmood","year":"2014","unstructured":"Mahmood I. Dosing in children: a critical review of the pharmacokinetic allometric scaling and modelling approaches in paediatric drug development and clinical settings. Clin Pharmacokinet. 2014;53:327\u201346.","journal-title":"Clin Pharmacokinet."},{"key":"291_CR3","doi-asserted-by":"crossref","DOI":"10.1201\/b14095","volume-title":"Pharmacokinetics","author":"M Gibaldi","year":"1982","unstructured":"Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker; 1982.","edition":"2"},{"key":"291_CR4","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/bja\/aen248","volume":"101","author":"KJ Anand","year":"2008","unstructured":"Anand KJ, Anderson BJ, Holford NH, NEOPAIN Trial Investigators Group, et al. Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. Br J Anaesth. 2008;101:680\u20139.","journal-title":"Br J Anaesth"},{"key":"291_CR5","unstructured":"Phoenix WinNonlin 8. Certara USA, Inc., Princeton."},{"key":"291_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40262-017-0569-6","volume":"57","author":"VC Ziesenitz","year":"2018","unstructured":"Ziesenitz VC, Vaughns JD, Koch G, Mikus G, van den Anker JN. Pharmacokinetics of fentanyl and its derivatives in children: a comprehensive review. Clin Pharmacokinet. 2018;57:125\u201349.","journal-title":"Clin Pharmacokinet"},{"key":"291_CR7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/bcp.12180","volume":"77","author":"C Wang","year":"2014","unstructured":"Wang C, Allegaert K, Peeters MY, et al. The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults. Br J Clin Pharmacol. 2014;77:149\u201359.","journal-title":"Br J Clin Pharmacol"},{"key":"291_CR8","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/jcph.652","volume":"56","author":"I Mahmood","year":"2016","unstructured":"Mahmood I. Prediction of drug clearance in premature and mature neonates, infants, and children \u2264 2\u00a0years of age: a comparison of the predictive performance of 4 allometric models. J Clin Pharmacol. 2016;56:733\u20139.","journal-title":"J Clin Pharmacol"},{"key":"291_CR9","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1365-2125.2004.02225.x","volume":"59","author":"S Bj\u00f6rkman","year":"2005","unstructured":"Bj\u00f6rkman S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol. 2005;59:691\u2013704.","journal-title":"Br J Clin Pharmacol"},{"key":"291_CR10","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1208\/s12248-014-9667-7","volume":"16","author":"I Mahmood","year":"2014","unstructured":"Mahmood I, Staschen CM, Goteti K. Prediction of drug clearance in children: an evaluation of the predictive performance of several models. AAPS J. 2014;16:1334\u201343.","journal-title":"AAPS J"},{"key":"291_CR11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1365-2125.2010.03802.x","volume":"71","author":"I Mahmood","year":"2011","unstructured":"Mahmood I. Evaluation of a morphine maturation model for the prediction of morphine clearance in children: how accurate is the predictive performance of the model? Br J Clin Pharmacol. 2011;71:88\u201394.","journal-title":"Br J Clin Pharmacol"},{"key":"291_CR12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1365-2125.2011.03984.x","volume":"72","author":"I Mahmood","year":"2011","unstructured":"Mahmood I. Response to the comments of Professors Anderson & Holford. Br J Clin Pharmacol. 2011;72:521\u20133.","journal-title":"Br J Clin Pharmacol"},{"key":"291_CR13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s40261-013-0097-6","volume":"33","author":"C Wang","year":"2013","unstructured":"Wang C, Sadhavisvam S, Krekels EH, Dahan A, Tibboel D, Danhof M, Vinks AA, Knibbe CA. Developmental changes in morphine clearance across the entire paediatric age range are best described by a bodyweight-dependent exponent model. Clin Drug Investig. 2013;33:523\u201334.","journal-title":"Clin Drug Investig"},{"key":"291_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/FTD.0b013e318042d3c4","volume":"29","author":"I Mahmood","year":"2007","unstructured":"Mahmood I. Prediction of drug clearance in children: Impact of allometric exponents, body weight and age. Therap Drug Monit. 2007;29:271\u20138.","journal-title":"Therap Drug Monit"},{"key":"291_CR15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1365-2125.2006.02622.x","volume":"61","author":"I Mahmood","year":"2006","unstructured":"Mahmood I. Prediction of drug clearance in children from adults: a comparison of several allometric methods. Br J Clin Pharmacol. 2006;61:545\u201357.","journal-title":"Br J Clin Pharmacol"},{"key":"291_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/jcph.1310","volume":"59","author":"I Mahmood","year":"2019","unstructured":"Mahmood I, Tegenge MA. A comparative study between allometric scaling and physiologically based pharmacokinetic modeling for the prediction of drug clearance from neonates to adolescents. J Clin Pharmacol. 2019;59:189\u201397.","journal-title":"J Clin Pharmacol"},{"key":"291_CR17","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/jcph.837","volume":"57","author":"I Mahmood","year":"2017","unstructured":"Mahmood I, Ahmad T, Mansoor N, Sharib SM. Prediction of clearance in neonates and infants (\u2264 3 months of age) for drugs that are glucuronidated: a comparative study between allometric scaling and physiologically based pharmacokinetic modeling. J Clin Pharmacol. 2017;57:476\u201383.","journal-title":"J Clin Pharmacol"},{"key":"291_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1515\/DMDI.2010.004","volume":"25","author":"I Mahmood","year":"2010","unstructured":"Mahmood I. Prediction of drug clearance in children 3\u00a0months and younger: an allometric approach. Drug Metabol Drug Interact. 2010;25:25\u201334.","journal-title":"Drug Metabol Drug Interact"},{"key":"291_CR19","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s13318-016-0372-z","volume":"42","author":"I Mahmood","year":"2017","unstructured":"Mahmood I. Prediction of clearance, volume of distribution, and half-life of drugs in extremely low to low birth weight neonates: an allometric approach. Eur J Drug Metab Pharmacokinet. 2017;42:601\u201310.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"291_CR20","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1002\/jcph.487","volume":"55","author":"I Mahmood","year":"2015","unstructured":"Mahmood I. Mechanistic versus allometric models for the prediction of drug clearance in neonates (<\u20093\u00a0months of age). J Clin Pharmacol. 2015;55:718\u201320.","journal-title":"J Clin Pharmacol"},{"key":"291_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-pharmtox-010510-100540","volume":"51","author":"M Rowland","year":"2011","unstructured":"Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol. 2011;51:45\u201373.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"291_CR22","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1517\/17425255.4.9.1143","volume":"4","author":"AN Edginton","year":"2008","unstructured":"Edginton AN, Theil FP, Schmitt W, Willmann S. Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol. 2008;4:1143\u201352.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"291_CR23","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1124\/dmd.115.065920","volume":"43","author":"JE Sager","year":"2015","unstructured":"Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N. Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification. Drug Metab Dispos. 2015;43:1823\u201337.","journal-title":"Drug Metab Dispos"},{"key":"291_CR24","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10928-012-9280-2","volume":"39","author":"Y Cao","year":"2012","unstructured":"Cao Y, Jusko WJ. Applications of minimal physiologically based pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2012;39:711\u201323.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"291_CR25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1023\/A:1026194618660","volume":"30","author":"S Bj\u00f6rkman","year":"2003","unstructured":"Bj\u00f6rkman S. Reduction and lumping of physiologically based pharmacokinetic models: prediction of the disposition of fentanyl and pethidine in humans by successively simplified models. J Pharmacokinet Pharmacodyn. 2003;30:285\u2013307.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"291_CR26","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s40262-017-0614-5","volume":"57","author":"SC van Dijkman","year":"2018","unstructured":"van Dijkman SC, de Jager NCB, Rauw\u00e9 WM, Danhof M, Della Pasqua O. Effect of age-related factors on the pharmacokinetics of lamotrigine and potential implications for maintenance dose optimization in future clinical trials. Clin Pharmacokinet. 2018;57:1039\u201353.","journal-title":"Clin Pharmacokinet"},{"key":"291_CR27","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/j.1365-2125.2011.03992.x","volume":"72","author":"M Cella","year":"2011","unstructured":"Cella M, Zhao W, Jacqz-Aigrain E, et al. Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations? Br J Clin Pharmacol. 2011;72:454\u201364.","journal-title":"Br J Clin Pharmacol"},{"key":"291_CR28","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/clpt.2009.107","volume":"86","author":"G Santen","year":"2009","unstructured":"Santen G, Horrigan J, Danhof M, et al. From trial and error to trial simulation. Part 2: an appraisal of current beliefs in the design and analysis of clinical trials for antidepressant drugs. Clin Pharmacol Ther. 2009;86:255\u201362.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"291_CR29","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s10928-018-9601-1","volume":"45","author":"PL Bonate","year":"2018","unstructured":"Bonate PL, Wang T, Passier P, Bagchus W, Burt H, L\u00fcpfert C, Abla N, Kovac J, Keiser J. Extrapolation of praziquantel pharmacokinetics to a pediatric population: a cautionary tale. J Pharmacokinet Pharmacodyn. 2018;45(5):747\u201362.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"291_CR30","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/jcph.837","volume":"57","author":"I Mahmood","year":"2017","unstructured":"Mahmood I, Ahmad T, Mansoor N, Sharib SM. Prediction of clearance in neonates and infants (\u2264 3 months of age) for drugs that are glucuronidated: a comparative study between allometric scaling and physiologically based pharmacokinetic modeling. J Clin Pharmacol. 2017;57(4):476\u201383.","journal-title":"J Clin Pharmacol"},{"key":"291_CR31","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/psp4.12385","volume":"8","author":"Q Wu","year":"2019","unstructured":"Wu Q, Peters SA. A retrospective evaluation of allometry, population pharmacokinetics, and physiologically-based pharmacokinetics for pediatric dosing using clearance as a surrogate. CPT Pharmacomet Syst Pharmacol. 2019;8:220\u20139.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"291_CR32","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1080\/01621459.1976.10480949","volume":"71","author":"GEP Box","year":"1976","unstructured":"Box GEP. Science and statistics. J Am Stat Assoc. 1976;71:791\u20139.","journal-title":"J Am Stat Assoc"}],"container-title":["Drugs in R&amp;D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-019-00291-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-019-00291-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-019-00291-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T01:09:39Z","timestamp":1607389779000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-019-00291-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,9]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["291"],"URL":"https:\/\/doi.org\/10.1007\/s40268-019-00291-2","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"type":"print","value":"1174-5886"},{"type":"electronic","value":"1179-6901"}],"subject":[],"published":{"date-parts":[[2019,12,9]]},"assertion":[{"value":"9 December 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Iftekhar Mahmood has no conflicts of interest that are directly relevant to the content of this article. Current position: Founder and CEO of Mahmood Clinical Pharmacology Consultancy, LLC, Rockville, MD, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"No sources of funding were used to conduct this study or prepare this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}